11,397 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Kennedy Capital Management LLC

Kennedy Capital Management LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,397 shares of the medical research company’s stock, valued at approximately $3,240,000.

Several other large investors also recently modified their holdings of AMGN. BOK Financial Private Wealth Inc. acquired a new position in Amgen during the fourth quarter worth about $29,000. United Community Bank acquired a new position in Amgen during the 4th quarter worth approximately $29,000. Horizon Financial Services LLC acquired a new stake in shares of Amgen during the 1st quarter valued at $28,000. Delos Wealth Advisors LLC boosted its stake in shares of Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 100 shares in the last quarter. Finally, Hartford Financial Management Inc. raised its holdings in Amgen by 56.9% in the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after buying an additional 41 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.69% of the stock is owned by company insiders.

Amgen Price Performance

NASDAQ AMGN traded up $1.40 during trading hours on Wednesday, reaching $334.68. The company’s stock had a trading volume of 360,658 shares, compared to its average volume of 2,630,480. Amgen Inc. has a 1 year low of $228.21 and a 1 year high of $346.85. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The company has a market capitalization of $179.53 billion, a price-to-earnings ratio of 47.61, a PEG ratio of 2.76 and a beta of 0.58. The firm’s 50-day moving average price is $314.69 and its 200-day moving average price is $297.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The firm had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.98 EPS. On average, equities research analysts predict that Amgen Inc. will post 19.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AMGN. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Mizuho boosted their target price on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. UBS Group raised their price target on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. BMO Capital Markets upped their price objective on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $230.00 to $300.00 in a research note on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $312.63.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.